Septic shock-3 vs 2: an analysis of the ALBIOS study

Date Issued
2018
Author(s)
Vasques, Francesco
Duscio, Eleonora
Pasticci, Iacopo
Caironi, Pietro
Meessen, Jennifer
Latini, Roberto
Cressoni, Massimo
Camporota, Luigi
Pesenti, Antonio
Fumagalli, Roberto
DOI
10.1186/s13054-018-2169-8
Abstract
A reanalysis of the ALBIOS trial suggested that patients with septic shock - defined by vasopressor-dependent hypotension in the presence of severe sepsis (Shock-2) - had a survival benefit when treated with albumin. The new septic shock definition (Shock-3) added the criterion of a lactate threshold of 2 mmol/L. We investigated how the populations defined according to Shock-2 and Shock-3 differed and whether the albumin benefit would be confirmed.
File(s)
No Thumbnail Available
Name

13054_2018_Article_2169.pdf

Size

1.13 MB

Checksum (MD5)

8ee27eb5d90da11dd11341c3d7bd3ddb

Download